NASDAQ · WHWK
Healthcare · Biotechnology
$4.04
Up+$0.06 (+1.49%)
Updated Sep 17, 2026, 7:49 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
WHWK closed at $4.04 after 20 trading sessions, down 17.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $4.11 | $4.16 | $4.03 | $4.04 | 170.64K |
| Sep 15, 2026 | $4.06 | $4.11 | $3.96 | $4.09 | 142.33K |
| Sep 14, 2026 | $4.16 | $4.1926 | $4.05 | $4.07 | 166.03K |
| Sep 11, 2026 | $4.12 | $4.30 | $4.08 | $4.11 | 283.52K |
| Sep 10, 2026 | $4.13 | $4.18 | $3.99 | $4.07 | 1.29M |
| Sep 9, 2026 | $4.39 | $4.4899 | $4.16 | $4.19 | 168.32K |
| Sep 8, 2026 | $4.56 | $4.6107 | $4.37 | $4.39 | 161.01K |
| Sep 4, 2026 | $4.59 | $4.65 | $4.53 | $4.60 | 178.14K |
| Sep 3, 2026 | $4.71 | $4.77 | $4.58 | $4.63 | 223.09K |
| Sep 2, 2026 | $4.66 | $4.81 | $4.53 | $4.71 | 138.97K |
| Sep 1, 2026 | $4.49 | $4.755 | $4.4409 | $4.63 | 202.77K |
| Aug 31, 2026 | $4.57 | $4.59 | $4.44 | $4.54 | 359.27K |
| Aug 28, 2026 | $4.87 | $5.0304 | $4.60 | $4.62 | 100.07K |
| Aug 27, 2026 | $4.83 | $4.9799 | $4.83 | $4.87 | 312.9K |
| Aug 26, 2026 | $5.08 | $5.10 | $4.83 | $4.84 | 136.26K |
| Aug 25, 2026 | $4.89 | $5.085 | $4.8891 | $5.08 | 167.97K |
| Aug 24, 2026 | $4.74 | $4.90 | $4.5406 | $4.88 | 240.09K |
| Aug 21, 2026 | $4.87 | $4.94 | $4.64 | $4.73 | 226.21K |
| Aug 20, 2026 | $4.83 | $4.93 | $4.71 | $4.83 | 293.37K |
| Aug 19, 2026 | $4.81 | $5.00 | $4.73 | $4.87 | 328.24K |
The latest Smart Investors Daily articles mentioning WHWK.
WHWK research
Company profile and research snapshot.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Leerink Partners | Outperform | — |
| Jun 25, 2026 | B. Riley Securities | Buy | — |
| Apr 16, 2026 | Citizens | Market Outperform | — |
| Dec 22, 2025 | Jones Trading | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
Whitehawk Therapeutics, Inc. (WHWK) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 1:05 PM EDTCompany ParticipantsScott...
Benzinga · Sep 14, 2026
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLCFindings Reinforce the Scientific Rationale for HWK-007, Whitehawk's
Yahoo · Sep 14, 2026
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant ADC target in patients with pretreated, EGFR wild-type non-small cell lung cancer (NSCLC). The data will be presented at the I
Yahoo · Sep 10, 2026
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WHWK.
